B and T Lymphocyte Attenuator is a Target of miR-155 during Naive CD4+ T Cell Activation
Authors
Abstract:
Background: MicroRNA-155 (miR-155) is upregulated during T cell activation, but the exact mechanisms by which it influences CD4+ T cell activation remain unclear. Objective: To examine whether the B and T lymphocyte attenuator (BTLA) is a target of miR-155 during naïve CD4+ T cell activation. Methods: Firefly luciferase reporter plasmids pEZX-MT01-wild-type-BTLA and pEZX-MT01-mutant-BTLA were constructed. Lymphocytes were nucleofected with miR-155 inhibitor or negative control (NC). Then, naïve CD4+ CD62L+ helper T cells purified from lymphocytes were stimulated with immobilized antibody to CD3 and soluble antibody to CD28. miR-155 and BTLA expression were examined by real-time RT-PCR. Cell surface CD69 expression and IL-2 secretion were measured by ELISA and flowcytometry, respectively. Results: Luciferase reporter assay showed that miR-155 targeted the BTLA 3’UTR region. Compared with non-stimulated condition, both miR-155 and BTLA mRNA expression were upregulated after T cell activation. Similar results were observed for BLTA protein expression. Compared with NC, the miR-155 inhibitor decreased miR-155 by about 45%, but did not influence BTLA mRNA expression. Compared with NC, the miR-155 inhibitor decreased the surface BTLA expression by about 60%. Upregulation of BTLA in miR-155 knockdown CD4+ T cells did not influence the cell surface expression of CD69, an early activation marker (p=0.523). Similarly, IL-2 production was not changed. Conclusion: miR-155 is involved in the inhibition of BTLA during CD4+ T cell activation. These results might serve as a basis for an eventual therapeutic manipulation of this pathway to treat inflammatory and autoimmune diseases.
similar resources
b and t lymphocyte attenuator is a target of mir-155 during naive cd4+ t cell activation
background: microrna-155 (mir-155) is upregulated during t cell activation, but the exact mechanisms by which it influences cd4+ t cell activation remain unclear. objective: to examine whether the b and t lymphocyte attenuator (btla) is a target of mir-155 during naïve cd4+ t cell activation. methods: firefly luciferase reporter plasmids pezx-mt01-wild-type-btla and pezx-mt01-mutant-btla were c...
full textA SURVEY OF CELLULAR IMMUNITY, TOTAL T-LYMPHOCYTE, T-ACTIVE , B-LYMPHOCYTE A ND T-CELL FUNCTION IN RELATION TO PHYTOHEMAGGLUTININ (PHA) IN THALASSEMIC PATIENTS
The aim of this study was to evaluate the immune system and lymphocyte function in 41 Iranian β-thalassemic patients and 50 controls, ages ranging from 2 to 18 years. The patients consisted of 20 splenectomized and 21 non-splenectomized patients. They were treated with Desferal, and had received repeated blood transfusion. Laboratory investigations included measurement of total T lymphocyt...
full textB and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells.
B and T lymphocyte attenuator (BTLA) was initially identified as expressed on Th1 cells and B cells, but recently reported to be expressed by macrophages, dendritic cells, and NK cells as well. To address this discrepancy we generated a panel of BTLA-specific mAbs and characterized BTLA expression under various activation conditions. We report the existence of three distinct BTLA alleles among ...
full textChronic Allostimulation during Attenuator in Sustaining Cell Survival Unexpected Role of B and T Lymphocyte
full text
B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.
B and T lymphocyte attenuator (BTLA), like its relative programmed cell death-1 (PD-1), is a receptor that negatively regulates murine T cell activation. However, its expression and function on human T cells is currently unknown. We report in this study on the expression of BTLA in human T cell subsets as well as its regulation on virus-specific T cells during primary human CMV infection. BTLA ...
full textMy Resources
Journal title
volume 13 issue 2
pages 89- 99
publication date 2016-06-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023